Chris joined Brandon Capital Partners in 2012.
Before this Chris was a Business Development Manager with CSL, Australia’s largest pharmaceutical company and one of the top 10 biotechnology companies in the world. At CSL Chris was responsible for identifying and reviewing opportunities for CSL’s global R&D pipeline. As a consequence Chris has extensive experience with both in-licensing and out-licensing therapeutic drugs and R&D enabling platforms. Earlier Chris spent three years as a postdoctoral scientist at The University of Cambridge, UK.
Chris is currently a director of; Aravax, Denteric, Ena Therapeutics, MecRx, Okogen and Q-Sera.
Chris has a Bachelor of Science (Honours) from The University of Melbourne, a PhD in Immunology conducted at the Walter and Eliza Hall Institute, and an MBA, specialising in innovation and entrepreneurship, from the University of Cambridge. Chris is a graduate of the Australian Institute of Company Directors.